Skip to content

Baseline Patterns of Substance Use Disorder Severity and Depression and Anxiety Symptoms Moderate the Efficacy of Mindfulness-Based Relapse Prevention

Corey Roos, Sarah Bowen, Katie Witkiewitz

Journal of Consulting and Clinical Psychology November 1, 2017 DOI: 10.1037/ccp0000249 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of two randomized controlled trials using latent class moderation Peer reviewed
Sample size 454
Population Adults with substance use disorders enrolled in two randomized trials (71.8% and 63.7% male; 48.4% and 44.6% non-White; mean ages 38.44 and 40.45 years)
Intervention Mindfulness-based relapse prevention (MBRP)
Measures Severity of Dependence Scale, Short Inventory of Problems, Beck Depression Inventory, Beck Anxiety Inventory
Topics Addiction Anxiety Depression Meditation
Key findings In both trials, three latent classes best characterized baseline symptom patterns. MBRP produced significant and large reductions in substance use outcomes in the high–high and high–low classes, but no effect in the low–low class, suggesting MBRP may be optimal for clients with severe substance use symptoms, with or without co-occurring depression and anxiety.

Abstract

Objective: Few studies have evaluated moderators of mindfulness-based relapse prevention (MBRP) for substance use disorders (SUDs). We tested whether baseline patterns of scores for SUD symptom severity and depression and anxiety symptoms moderated the efficacy of MBRP.

Method: We used a latent class moderation approach with data from a randomized trial of MBRP compared to cognitive–behavioral relapse prevention and treatment as usual (TAU; Bowen et al., 2014; N = 286, 71.8% male, 48.4% non-White, mean age = 38.44 years, SD = 10.92) and a randomized trial comparing MBRP to TAU (Bowen et al., 2009; N = 168, 63.7% male, 44.6% non-White, mean age = 40.45, SD = .28). Indicators for the latent class models were measures of SUD severity (Severity of Dependence Scale and Short Inventory of Problems), depression symptoms (Beck Depression Inventory), and anxiety symptoms (Beck Anxiety Inventory).

Results: In both trials, 3 latent classes provided the best fit: a high–high class characterized by high SUD severity and depression and anxiety symptoms, a high–low class characterized by high SUD severity and low depression and anxiety symptoms, and a low–low class characterized by low SUD severity and depression and anxiety symptoms. In both trials, we found significant latent Class × Treatment interaction effects: There were significant and large effects of MBRP on substance use outcomes in the high–high and high–low classes, but no MBRP effect in the low–low class.

Conclusion: MBRP may be an optimal treatment for preventing relapse among clients with severe levels of SUD symptoms and depression and anxiety symptoms, as well as clients with only severe SUD symptoms.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Cited by 16

and 11 more in the library

Cites 7

and 2 more in the library

Explore topics